uniQure N.V.
Organization details
- Legal name
- uniQure N.V.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Headquarters city
- Amsterdam
- Headquarters country
- Netherlands
- Fiscal year end
- December
- Ticker symbol
- QURE
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001590560
Board of directors
-
David D. Meek · DirectorSince 2023
-
Jack Kaye · DirectorSince 2023
-
Jeremy P. Springhorn · DirectorSince 2023
-
Leonard E. Post · DirectorSince 2023
-
Madhavan Balachandran · DirectorSince 2023
-
Matthew C. Kapusta · Director · CEO, Managing DirectorSince 2023
-
Paula Soteropoulos · DirectorSince 2023
-
Rachelle Suzanne Jacques · DirectorSince 2023
-
Robert Gut · DirectorSince 2023
Chief executives
Board connections
6 of this board's directors also sit on 9 other boards. 9 are in the same sector.
-
Akari Therapeutics plc Same sectorvia Rachelle Suzanne Jacques
-
CG Oncology Inc. Same sectorvia Leonard E. Post
-
Corbus Pharmaceuticals Holdings Inc. Same sectorvia Rachelle Suzanne Jacques
-
Cullinan Therapeutics Inc. Same sectorvia David D. Meek
-
Dianthus Therapeutics Inc. Same sectorvia Paula Soteropoulos
-
Dyadic International Inc. Same sectorvia Jack Kaye
-
Rallybio Corporation Same sectorvia Paula Soteropoulos
-
Replimune Group Inc. Same sectorvia Madhavan Balachandran
-
Stevanato Group S.p.A. Same sectorvia Madhavan Balachandran
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $20,234,835
- 53 sales by 12 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 6, 2026 | David D. Meek Director | Open-market sale | −9,080 | $21.25 | $192,950 |
| Oct 30, 2026 | Abi-Saab Walid Officer (Chief Medical Officer) | Grant or award | +18,750 | — | — |
| Jul 2, 2026 | Matthew C. Kapusta Director, Officer (CEO, Managing Director) | Option exercise | +21,082 | $19.39 | $408,780 |
| Jul 2, 2026 | Matthew C. Kapusta Director, Officer (CEO, Managing Director) | Open-market sale | −9,200 | $44.43 | $408,756 |
| Jul 2, 2026 | Matthew C. Kapusta Director, Officer (CEO, Managing Director) | Open-market sale | −4,282 | $45.43 | $194,531 |
| Jul 2, 2026 | Matthew C. Kapusta Director, Officer (CEO, Managing Director) | Open-market sale | −7,600 | $45.89 | $348,764 |
| Jun 30, 2026 | Abi-Saab Walid Officer (Chief Medical Officer) | Option exercise | +10,000 | $5.59 | $55,900 |
| Jun 30, 2026 | Jack Kaye Director | Option exercise | +4,107 | $37.00 | $151,959 |
| Jun 30, 2026 | Abi-Saab Walid Officer (Chief Medical Officer) | Open-market sale | −10,000 | $46.46 | $464,600 |
| Jun 30, 2026 | Jack Kaye Director | Open-market sale | −4,107 | $46.49 | $190,934 |
| Jun 30, 2026 | Abi-Saab Walid Officer (Chief Medical Officer) | Open-market sale | −20,000 | $46.40 | $928,000 |
| Jun 30, 2026 | Jack Kaye Director | Option exercise | +17,060 | $20.18 | $344,271 |
| Jun 30, 2026 | Jack Kaye Director | Open-market sale | −17,060 | $46.43 | $792,096 |
| Jun 26, 2026 | Abi-Saab Walid Officer (Chief Medical Officer) | Open-market sale | −1,434 | $46.86 | $67,197 |
| Jun 25, 2026 | Matthew C. Kapusta Director, Officer (CEO, Managing Director) | Option exercise | +28,716 | $31.71 | $910,584 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about uniQure N.V.
Who is the CEO of uniQure N.V.?
Matthew C. Kapusta is uniQure N.V.'s CEO, Managing Director.
How many directors are on uniQure N.V.'s board?
uniQure N.V.'s board has 9 directors: David D. Meek, Jack Kaye, Jeremy P. Springhorn, Leonard E. Post, Madhavan Balachandran, Matthew C. Kapusta, Paula Soteropoulos, Rachelle Suzanne Jacques and Robert Gut.
Are uniQure N.V. insiders buying or selling shares?
Over the last 12 months, uniQure N.V. insiders made no open-market purchases and sold $20.2 million of shares in 53 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="uniqure-nv"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.